




ENVISAGE



Overview

- **Mission:** Advance the strategic growth and exits of Newcos:
 - Value creation
 - Capital efficiency
 - Risk management
 - Timelines and returns
- **Value Proposition:**
 - Experienced operations and roaming executive team
 - Quality of Newcos
 - Interdisciplinary key opinion leader (KOL) networks
- **Strategic Areas of Interest:**
 - Therapeutics (small molecule and biologics)
 - Diagnostics (biomarkers and point of care diagnostic platforms)

Sourcing Early Stage Opportunities




- Experienced KOL scientific insights and technical evaluation
- Project based, asset-centric Newcos
- Leverage preferred network of vendors for product development
- Balanced deal flow and pipeline for optimized returns

Connecting Regional Assets

Collaborative "Cluster" to Create Value-Add Newcos

- Cardio-Metabolic
- Immunology
- Neurosciences
- Infectious diseases



- R&D labs
- GLP toxicology/assays
- GMP manufacturing
- Regulatory & clinical
- Legal/Finance/Acct

- Translational scientists
- Researchers
- Process development
- Clinical



Core Team

Managing Partners

Vik Subbu
Operations - Business

- Former Dir., Business Development
- Former Mgr., Corporate Strategic Investments



Joseph Hsiao, JD
Operations - Legal and IP

- Registered Patent Agent and Attorney
- Former Patent Attorney , Sughrue Mion LLC



Board Advisors

Gary Fanger PhD
Life sciences

- Chief Executive Officer
- Former SVP and Chief Operating Officer
- Former VP of Business Development, MacroGenics



Michael Richman
Life sciences

- President and CEO
- Former Chief Operating Officer
- Former SVP of Corporate Development



Steven Chatfield PhD
Life sciences (UK)

- Former EVP, Strategic Investments,
- Former Ex. Dir. - UK Health Protection Agency (HPA)



Core Team Experience

- Team with > 30 years of combined life sciences and executive level expertise
- Start-up minded professionals
- Successful track record in identifying and building value in early stage Newcos
- Clear understanding of the timelines and deliverables to pharma
- Experienced business development and operations team with deal experience :
 - Team that led Amplimmune acquisition by AstraZeneca/MedImmune in Sep 2013
 - *Alli* 2014 Breakthrough Award for Deal of the Year – Best Deal of the Year
- Established relationships with reputable product development partners

Value Proposition to Stakeholders

- **Strategic Pharma Partners**
 - Continuous pipeline deal flow of innovative, *de-risked* technologies
 - Input into the Newco selection process
 - Option-based deals
 - Opportunity to explore innovations outside of core areas of interest
- **Academia**
 - Increased revenue from monetization of assets
 - Streamline Newco formation process
 - Sponsored research collaborations and agreements (when applicable)
 - Continued inventor involvement in Newco
- **Seed and Early stage Newcos**
 - Operations, business and roaming executive team with significant start-up experience
 - Access to capital and strategic partnerships
 - Enables founders to focus on science and product development

Streamlined Product Development via Preferred Vendors


ENVISAGE



- Outline clear R&D plan to reach milestones to include:
 - Timelines and budgets
 - Regulatory requirements
 - Key mechanism of action (MOA) experiments

Current Portfolio – *Pre-Seed Stage*

Established process for evaluating and selecting assets



Current Status and Next Steps

- ✓ Recruited an experienced operations and roaming executive team
 - ✓ Leveraged KOLs as consultants in review and identification of technologies
 - ✓ Identified technologies in areas of diagnostic and therapeutic interests
 - ✓ Established preferred partnerships
- Seeking seed funding or strategic partner to advance current portfolio